遅発性ジスキネジア治療薬の世界市場レポート：動向、予測、競合分析（～2031年）

遅発性ジスキネジア治療薬の世界市場の将来は、病院や診療所市場での機会で有望視されています。世界の遅発性ジスキネジア治療薬の市場規模は、2025年～2031年にCAGR4.5％で成長すると予測されます。この市場の主な促進要因は、統合失調症などの疾患の有病率の上昇と、ヘルスケア提供者や患者の意識の高まりです。

• Lucintelの予測では、タイプ別ではVmat2阻害剤が予測期間中に最も高い成長を遂げる見込みです。
• 用途別では、病院が高い成長を遂げると予想されています。
• 地域別では、アジア太平洋が予測期間中に最も高い成長が見込まれます。

遅発性ジスキネジア治療薬市場の新たな動向

遅発性ジスキネジア治療薬の治療状況は急速に進化しており、いくつかの新たな動向が世界中でこの疾患の管理方法に影響を与えています。これらの動向は、薬剤開発、デジタルヘルス技術、患者中心のケアの進歩によって形成されており、TDに罹患した人々の治療結果とQOLを改善する新たな機会を生み出しています。

• FDA承認薬の採用拡大：バルベナジンやドイテトラベナジンのようなFDA承認薬は、遅発性ジスキネジアの治療方法を変革しています。これらの薬剤は特にドパミン系を標的とし、旧来の薬剤と比較して副作用が少なく、症状に的を絞った治療を提供します。これらの薬剤の採用が増加し、治療成績と患者の満足度が向上するとともに、遅発性ジスキネジアの全体的な管理が強化されつつあります。この動向は、より多くの治療法が承認され市場に参入するにつれて、さらに続くと予想されます。
• 個別化医療の成長：個別化医療はTD治療市場における重要な動向であり、個々の患者のプロファイルに基づいて治療動向を調整することに重点を置いています。遺伝的体質、併存疾患、疾患の重症度などの要素を考慮することで、ヘルスケア提供者は患者ごとに最も効果的な治療法を選択することができます。このアプローチは、TDの治療において特に重要です。TDの重症度や治療に対する反応には個人差があるからです。個別化医療は予後を改善し、神経疾患の治療に関連しがちな試行錯誤のプロセスを減らす可能性が高いです。
• デジタルヘルスツールの役割の拡大：遅発性ジスキネジアの管理において、デジタルヘルス技術が果たす役割はますます重要になってきています。モバイルアプリや遠隔医療は、医師が遠隔で患者の経過をモニタリングし、リアルタイムで治療を調整するのに役立っています。デジタルツールはまた、患者が自分の症状を追跡するためのリソースを提供し、治療計画への関与とアドヒアランスを向上させます。このような技術が進歩し続ければ、TD患者のケアはさらに向上し、治療効果に関する貴重な知見が得られると思われます。
• 併用療法の開発：複数の治療法を併用する併用療法の動向は、TD治療市場で勢いを増しています。ドパミン受容体拮抗薬と他の神経保護薬など、症状の異なる側面を標的とする薬剤を併用することで、患者はより包括的な症状緩和を得ることができます。併用療法は臨床試験でも検討されており、特に重症の患者において遅発性ジスキネジアをよりよくコントロールできる可能性があります。
• 早期診断と予防への重点化：遅発性ジスキネジアの進行を予防するためには、早期診断と介入が重要です。高度な画像診断技術や早期スクリーニングツールによる診断精度の向上が重視されるようになってきています。早期介入は症状の重篤度を軽減し、不可逆的な障害を予防するのに役立ち、患者の長期予後を改善します。この動向は、意識を高め、積極的な治療を奨励するために活動しているヘルスケア提供者や患者支援団体によって支えられています。

こうした新たな動向により、遅発性ジスキネジアの治療環境は、より的を絞った、個別化された、利用しやすい治療の選択肢を提供することで再構築されつつあります。新しい治療法や技術が開発され続けることで、患者はより良い症状管理の機会を得ることができ、ヘルスケアシステムはより効率的で患者中心のケアを提供できるようになると思われます。

遅発性ジスキネジア治療薬市場の最近の発展

遅発性ジスキネジア治療薬市場には、イノベーションを促進し、この疾患に罹患した患者へのケアを改善するいくつかの主要な発展が見られます。これらの発展は、治療効果の向上、アンメットニーズへの対応、患者の治療アクセスの拡大に焦点を当てています。

• 新薬の承認：バルベナジンやドイテトラベナジンのような新薬の承認は、遅発性ジスキネジアの治療に大きな変化をもたらしました。これらの薬剤は脳内のドパミン受容体を特異的に標的として不随意運動を抑制するため、従来の治療法よりも効果的な治療選択肢を提供します。この薬剤の承認により、遅発性ジスキネジアの治療法にパラダイムシフトが起こり、患者により効果的で安全な選択肢が提供されるようになりました。
• 神経調節技術の進歩：脳深部刺激療法（DBS）や経頭蓋磁気刺激療法（TMS）などのニューロモデュレーションが遅発性ジスキネジアの治療法として注目されています。これらの技術は、脳活動を調節してTDの症状を緩和することを目的としています。神経調節の有効性を検討する臨床試験では有望な結果が得られており、薬物療法に反応しない患者に対する治療の選択肢が広がる可能性があります。
• 遺伝子治療の研究増加：遺伝子治療は遅発性ジスキネジアに対する長期的な解決策の可能性が出てきています。この分野の研究は、TDの根本的な遺伝的原因を改善する治療法の開発に焦点を当てています。TDに対する遺伝子治療はまだ初期段階にありますが、現在進行中の研究では、この神経疾患の患者により的を絞った効果的な治療を提供できる可能性が模索されています。
• 診断ツールの改善：機能的MRIやその他の画像技術などの診断ツールの進歩により、遅発性ジスキネジアを早期に発見する能力が向上しています。早期の発見は、病態の進行を予防するためのタイムリーな介入を可能にするため、遅発性ジスキネジアを効果的に管理する上で極めて重要です。診断ツールの改善により、TDの診断精度が向上し、ヘルスケア提供者はより良いケアを提供できるようになりました。
• 患者中心のケアの重視：遅発性ジスキネジア患者に対する患者中心のケアへの注目が高まっています。ヘルスケア提供者は遅発性ジスキネジアを管理するために、薬物療法だけでなく、生活習慣への介入、心理的サポート、患者教育などを含む、より全体的なアプローチを採用しています。このようなアプローチは、TD患者の全体的なQOLを向上させ、治療計画を個々のニーズに合わせたものにすることを目的としています。

このような主な発展により、遅発性ジスキネジアに対する治療の有効性と利用しやすさが向上しています。新しい薬剤、技術、治療戦略が進化し続けるにつれて、TDの管理はより個別化され、効果的なものとなり、患者にとってより良い転帰につながっています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 背景と分類
• サプライチェーン

第3章 市場動向と予測分析

• マクロ経済の動向と予測
• 業界の促進要因と課題
• PESTLE分析
• 特許分析
• 規制環境

第4章 世界の遅発性ジスキネジア治療薬市場：タイプ別

• 概要
• タイプ別の魅力分析
• 小胞モノアミントランスポーター2（Vmat2）阻害剤：動向と予測（2019-2031年）
• ボツリヌス毒素：動向と予測（2019年～2031年）
• その他：動向と予測（2019年～2031年）

第5章 世界の遅発性ジスキネジア治療薬市場：用途別

• 概要
• 用途別の魅力分析
• 病院：動向と予測（2019年～2031年）
• 診療所：動向と予測（2019年～2031年）
• その他：動向と予測（2019年～2031年）

第6章 地域分析

• 概要
• 世界の遅発性ジスキネジア治療薬市場：地域別

第7章 北米の遅発性ジスキネジア治療薬市場

• 概要
• 北米の遅発性ジスキネジア治療薬市場（タイプ別）
• 北米の遅発性ジスキネジア治療薬市場（用途別）
• 米国の遅発性ジスキネジア治療薬市場
• メキシコの遅発性ジスキネジア治療薬市場
• カナダの遅発性ジスキネジア治療薬市場

第8章 欧州の遅発性ジスキネジア治療薬市場

• 概要
• 欧州の遅発性ジスキネジア治療薬市場（タイプ別）
• 欧州の遅発性ジスキネジア治療薬市場（用途別）
• ドイツの遅発性ジスキネジア治療薬市場
• フランスの遅発性ジスキネジア治療薬市場
• スペインの遅発性ジスキネジア治療薬市場
• イタリアの遅発性ジスキネジア治療薬市場
• 英国の遅発性ジスキネジア治療薬市場

第9章 アジア太平洋の遅発性ジスキネジア治療薬市場

• 概要
• アジア太平洋の遅発性ジスキネジア治療薬市場（タイプ別）
• アジア太平洋の遅発性ジスキネジア治療薬市場（用途別）
• 日本の遅発性ジスキネジア治療薬市場
• インドの遅発性ジスキネジア治療薬市場
• 中国の遅発性ジスキネジア治療薬市場
• 韓国の遅発性ジスキネジア治療薬市場
• インドネシアの遅発性ジスキネジア治療薬市場

第10章 世界のその他地域の遅発性ジスキネジア治療薬市場

• 概要
• 世界のその他地域の遅発性ジスキネジア治療薬市場（タイプ別）
• 世界のその他地域の遅発性ジスキネジア治療薬市場（用途別）
• 中東の遅発性ジスキネジア治療薬市場
• 南米の遅発性ジスキネジア治療薬市場
• アフリカの遅発性ジスキネジア治療薬市場

第11章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析
  • 競争企業間の敵対関係
  • 買い手の交渉力
  • 供給企業の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
• 市場シェア分析

第12章 機会と戦略分析

• バリューチェーン分析
• 成長機会分析
  • タイプ別の成長機会
  • 用途別の成長機会
• 世界の遅発性ジスキネジア治療薬市場における新たな動向
• 戦略分析
  • 新製品開発
  • 認証とライセンシング
  • 合併、買収、契約、提携、合弁事業

第13章 バリューチェーンにおける主要企業プロファイル

• 競合分析
• Teva Pharmaceutical
• Neurocrine Biosciences
• Sun Pharmaceutical
• SteriMax
• Adamas Pharmaceuticals

第14章 付録

• 図一覧
• 表一覧
• 調査手法
• 免責事項
• 著作権
• 略語および技術単位
• Lucintelについて
• お問い合わせ

List of Figures

• Figure 1.1: Trends and Forecast for the Global Tardive Dyskinesia Treatment Medicine Market
• Figure 2.1: Usage of Tardive Dyskinesia Treatment Medicine Market
• Figure 2.2: Classification of the Global Tardive Dyskinesia Treatment Medicine Market
• Figure 2.3: Supply Chain of the Global Tardive Dyskinesia Treatment Medicine Market
• Figure 2.4: Driver and Challenges of the Tardive Dyskinesia Treatment Medicine Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 4.1: Global Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Type
• Figure 4.3: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Type
• Figure 4.4: Trends and Forecast for Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 4.5: Trends and Forecast for Botulinum Toxin in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 4.6: Trends and Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 5.1: Global Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Application
• Figure 5.3: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Application
• Figure 5.4: Trends and Forecast for Hospital in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 5.5: Trends and Forecast for Clinic in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 5.6: Trends and Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 6.1: Trends of the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Region (2025-2031)
• Figure 7.1: Trends and Forecast for the North American Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 7.2: North American Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
• Figure 7.3: Trends of the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
• Figure 7.4: Forecast for the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
• Figure 7.5: North American Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
• Figure 7.6: Trends of the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
• Figure 7.7: Forecast for the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
• Figure 7.8: Trends and Forecast for the United States Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Mexican Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 7.10: Trends and Forecast for the Canadian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 8.1: Trends and Forecast for the European Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 8.2: European Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
• Figure 8.3: Trends of the European Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
• Figure 8.4: Forecast for the European Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
• Figure 8.5: European Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
• Figure 8.6: Trends of the European Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
• Figure 8.7: Forecast for the European Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
• Figure 8.8: Trends and Forecast for the German Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the French Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Spanish Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the Italian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 8.12: Trends and Forecast for the United Kingdom Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 9.1: Trends and Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 9.2: APAC Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
• Figure 9.3: Trends of the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
• Figure 9.4: Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
• Figure 9.5: APAC Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
• Figure 9.6: Trends of the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
• Figure 9.7: Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
• Figure 9.8: Trends and Forecast for the Japanese Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Indian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the Chinese Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the South Korean Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 9.12: Trends and Forecast for the Indonesian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 10.1: Trends and Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Figure 10.2: ROW Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
• Figure 10.3: Trends of the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
• Figure 10.4: Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
• Figure 10.5: ROW Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
• Figure 10.6: Trends of the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
• Figure 10.7: Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
• Figure 10.8: Trends and Forecast for the Middle Eastern Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the South American Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 10.10: Trends and Forecast for the African Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Tardive Dyskinesia Treatment Medicine Market
• Figure 11.2: Market Share (%) of Top Players in the Global Tardive Dyskinesia Treatment Medicine Market (2024)
• Figure 12.1: Growth Opportunities for the Global Tardive Dyskinesia Treatment Medicine Market by Type
• Figure 12.2: Growth Opportunities for the Global Tardive Dyskinesia Treatment Medicine Market by Application
• Figure 12.3: Growth Opportunities for the Global Tardive Dyskinesia Treatment Medicine Market by Region
• Figure 12.4: Emerging Trends in the Global Tardive Dyskinesia Treatment Medicine Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Tardive Dyskinesia Treatment Medicine Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Tardive Dyskinesia Treatment Medicine Market by Region
• Table 1.3: Global Tardive Dyskinesia Treatment Medicine Market Parameters and Attributes
• Table 3.1: Trends of the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 3.2: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Tardive Dyskinesia Treatment Medicine Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 4.4: Trends of Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 4.5: Forecast for Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 4.6: Trends of Botulinum Toxin in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 4.7: Forecast for Botulinum Toxin in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 4.8: Trends of Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 4.9: Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Tardive Dyskinesia Treatment Medicine Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 5.4: Trends of Hospital in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 5.5: Forecast for Hospital in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 5.6: Trends of Clinic in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 5.7: Forecast for Clinic in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 5.8: Trends of Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 5.9: Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 7.1: Trends of the North American Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 7.2: Forecast for the North American Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 8.1: Trends of the European Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 8.2: Forecast for the European Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 9.1: Trends of the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 9.2: Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 10.1: Trends of the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 10.2: Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Tardive Dyskinesia Treatment Medicine Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Tardive Dyskinesia Treatment Medicine Market (2019-2031)
• Table 11.1: Product Mapping of Tardive Dyskinesia Treatment Medicine Suppliers Based on Segments
• Table 11.2: Operational Integration of Tardive Dyskinesia Treatment Medicine Manufacturers
• Table 11.3: Rankings of Suppliers Based on Tardive Dyskinesia Treatment Medicine Revenue
• Table 12.1: New Product Launches by Major Tardive Dyskinesia Treatment Medicine Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Tardive Dyskinesia Treatment Medicine Market

The future of the global tardive dyskinesia treatment medicine market looks promising with opportunities in the hospital and clinic markets. The global tardive dyskinesia treatment medicine market is expected to grow with a CAGR of 4.5% from 2025 to 2031. The major drivers for this market are the rising prevalence of conditions like schizophrenia and increased awareness among healthcare providers and patients.

• Lucintel forecasts that, within the type category, Vmat2 inhibitors are expected to witness the highest growth over the forecast period.
• Within the application category, hospitals are expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Tardive Dyskinesia Treatment Medicine Market

The treatment landscape for tardive dyskinesia treatment medicine is rapidly evolving, with several emerging trends influencing how the condition is managed across the globe. These trends are shaped by advancements in drug development, digital health technologies, and patient-centered care, creating new opportunities for improving treatment outcomes and quality of life for those affected by TD.

• Increased Adoption of FDA-Approved Medications: FDA-approved medications like valbenazine and deutetrabenazine are transforming the way tardive dyskinesia is treated. These drugs specifically target the dopamine system, offering targeted treatment for symptoms with fewer side effects compared to older medications. Their growing adoption is improving treatment outcomes and patient satisfaction while enhancing the overall management of TD. This trend is expected to continue as more treatments receive approval and enter the market.
• Growth of Personalized Medicine: Personalized medicine is a key trend in the TD treatment market, focusing on tailoring therapies based on individual patient profiles. By considering factors such as genetic makeup, comorbidities, and disease severity, healthcare providers can select the most effective treatments for each patient. This approach is particularly important in the treatment of TD, as the condition varies in severity and response to treatment among individuals. Personalized medicine is likely to improve outcomes and reduce the trial-and-error process often associated with treating neurological disorders.
• Expanding Role of Digital Health Tools: Digital health technologies are playing an increasingly important role in managing tardive dyskinesia. Mobile apps and telemedicine are helping doctors remotely monitor patient progress and adjust treatments in real-time. Digital tools also provide patients with resources to track their symptoms, improving engagement and adherence to treatment plans. As these technologies continue to improve, they will further enhance care delivery for individuals living with TD and provide valuable insights into treatment effectiveness.
• Development of Combination Therapies: The trend toward combination therapies, where multiple treatment modalities are used together, is gaining momentum in the TD treatment market. By combining medications that target different aspects of the condition-such as dopamine receptor antagonists with other neuroprotective drugs-patients can achieve more comprehensive symptom relief. Combination therapies are also being explored in clinical trials, offering hope for better control of tardive dyskinesia, especially in patients with severe cases.
• Increased Focus on Early Diagnosis and Prevention: Early diagnosis and intervention are crucial for preventing the progression of tardive dyskinesia. There is a growing emphasis on improving diagnostic accuracy through advanced imaging techniques and early screening tools. Early intervention can help reduce the severity of symptoms and prevent irreversible damage, thus enhancing the long-term prognosis for patients. This trend is being supported by healthcare providers and patient advocacy organizations that are working to raise awareness and encourage proactive care.

These emerging trends are reshaping the treatment landscape for tardive dyskinesia by offering more targeted, personalized, and accessible treatment options. As new therapies and technologies continue to develop, patients will have improved chances for better symptom management, and healthcare systems will be able to offer more efficient and patient-centered care.

Recent Developments in the Tardive Dyskinesia Treatment Medicine Market

The tardive dyskinesia treatment medicine market is witnessing several key developments, which are driving innovation and improving care for individuals affected by this condition. These developments are focused on enhancing treatment efficacy, addressing unmet needs, and expanding patient access to care.

• Approval of New Medications: The approval of new medications like valbenazine and deutetrabenazine has significantly transformed the treatment of tardive dyskinesia. These drugs specifically target dopamine receptors in the brain to reduce involuntary movements, providing more effective treatment options than older therapies. Their approval has led to a paradigm shift in how TD is managed, offering patients more effective and safer options.
• Advances in Neuromodulation Techniques: Neuromodulation, including deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS), is gaining attention as a potential treatment for tardive dyskinesia. These techniques aim to regulate brain activity to alleviate symptoms of TD. Clinical trials investigating the efficacy of neuromodulation are showing promising results, which could expand treatment options for patients who do not respond to pharmacological therapies.
• Increased Research in Gene Therapy: Gene therapy is emerging as a potential long-term solution for tardive dyskinesia. Research in this area is focused on developing treatments that can correct the underlying genetic causes of TD. Although gene therapy for TD is still in its early stages, ongoing studies are exploring its potential to offer more targeted and effective treatments for patients with this neurological disorder.
• Improved Diagnostic Tools: Advances in diagnostic tools, such as functional MRI and other imaging techniques, are improving the ability to identify tardive dyskinesia in its early stages. Early detection is crucial for managing TD effectively, as it allows for timely intervention that can prevent the progression of the condition. Improved diagnostic tools are enhancing the accuracy of TD diagnoses and enabling healthcare providers to offer better care.
• Focus on Patient-Centered Care: There is an increasing focus on patient-centered care for individuals with tardive dyskinesia. Healthcare providers are adopting more holistic approaches to managing TD, which include not only pharmacological treatment but also lifestyle interventions, psychological support, and patient education. This approach aims to improve the overall quality of life for TD patients and ensure that treatment plans are tailored to individual needs.

These key developments are enhancing the effectiveness and accessibility of treatments for tardive dyskinesia. As new medications, technologies, and treatment strategies continue to evolve, the management of TD is becoming more personalized and effective, leading to better outcomes for patients.

Strategic Growth Opportunities in the Tardive Dyskinesia Treatment Medicine Market

The tardive dyskinesia treatment medicine market offers numerous growth opportunities across key applications driven by technological advancements, increased awareness, and improved access to healthcare. Companies are focusing on innovative treatment strategies to address the unmet needs of patients and expand their market share.

• Expansion of Novel Drug Therapies: The development of new drug therapies, including dopamine receptor antagonists and other innovative molecules, offers significant growth potential in the market. Pharmaceutical companies that invest in these treatments can capitalize on the increasing demand for more effective TD therapies, especially as new medications receive regulatory approval and enter the market.
• Growth of Personalized Treatment Approaches: Personalized medicine, where treatments are tailored to individual patient profiles, presents a growth opportunity for the TD treatment market. By incorporating genetic testing and patient-specific factors, personalized approaches can lead to better treatment outcomes. This trend will become increasingly important as healthcare providers seek to provide more effective and individualized care.
• Leveraging Digital Health Solutions: The integration of digital health solutions, such as telemedicine and mobile apps, into TD treatment offers significant growth opportunities. Digital health tools can assist in patient monitoring, symptom tracking, and providing real-time feedback, improving treatment adherence and patient engagement. These solutions are expected to become a key part of TD management strategies.
• Market Expansion in Emerging Regions: Expanding access to treatment in emerging regions, such as Asia and Latin America, offers substantial growth opportunities for pharmaceutical companies. Rising healthcare infrastructure and increasing awareness of tardive dyskinesia are expected to drive demand for new treatments in these regions. Companies that can offer affordable and effective therapies will benefit from this growth.
• Focus on Post-Treatment Care: The growing emphasis on post-treatment care, which includes patient support programs, ongoing monitoring, and rehabilitation, offers additional growth opportunities. Post-treatment care is essential for ensuring that patients maintain the benefits of their therapies and improve their long-term quality of life.

These strategic growth opportunities are shaping the future of the tardive dyskinesia treatment medicine market by driving innovation and expanding access to more effective and personalized treatments. Companies that capitalize on these trends will be well-positioned for success in the evolving TD treatment landscape.

Tardive Dyskinesia Treatment Medicine Market Driver and Challenges

The tardive dyskinesia treatment medicine market is influenced by several technological, economic, and regulatory factors. Understanding the key drivers and challenges is essential for navigating the market and developing effective solutions to address the needs of patients.

The factors responsible for driving the tardive dyskinesia treatment medicine market include:

1. Advances in Drug Development: The development of new drug therapies, including biologics and dopamine receptor antagonists, is driving growth in the market. These innovations provide more effective treatment options for TD, improving patient outcomes and expanding treatment choices.

2. Increased Awareness and Diagnosis: As awareness of tardive dyskinesia increases among healthcare providers and patients, earlier diagnosis and more timely interventions are leading to better management of the condition. This trend is expanding the market for TD treatments.

3. Rising Prevalence of Antipsychotic Use: The widespread use of antipsychotic medications, which are associated with tardive dyskinesia, is contributing to a higher prevalence of the condition. As more people are affected by TD, the demand for treatment options continues to rise.

4. Improved Regulatory Approvals: The faster regulatory approval processes for new treatments are allowing innovative therapies to reach the market more quickly, benefiting patients with tardive dyskinesia and driving market growth.

5. Focus on Personalized Treatment: Personalized treatment approaches, which consider individual patient needs, are improving the effectiveness of TD management. This trend is contributing to the growing demand for targeted therapies in the market.

Challenges in the tardive dyskinesia treatment medicine market are:

1. High Treatment Costs: The high cost of some of the newer medications, particularly biologics, is a major challenge for patients, especially in developing countries. These costs can limit access to treatment and hinder market growth.

2. Regulatory Barriers: Strict regulatory requirements and long approval timelines for new therapies can delay the introduction of innovative treatments, creating a barrier to market expansion.

3. Limited Awareness in Some Regions: In some regions, there is a lack of awareness about tardive dyskinesia, which can result in delayed diagnoses and treatment. This limits the market's potential in those areas.

The tardive dyskinesia treatment medicine market is shaped by advancements in drug development, increased awareness, and regulatory progress. However, challenges such as high treatment costs, regulatory barriers, and limited awareness in certain regions must be addressed to unlock the full potential of the market.

List of Tardive Dyskinesia Treatment Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, tardive dyskinesia treatment medicine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tardive dyskinesia treatment medicine companies profiled in this report include:

• Teva Pharmaceutical
• Neurocrine Biosciences
• Sun Pharmaceutical
• SteriMax
• Adamas Pharmaceuticals

Tardive Dyskinesia Treatment Medicine Market by Segment

The study includes a forecast for the global tardive dyskinesia treatment medicine market by type, application, and region.

Tardive Dyskinesia Treatment Medicine Market by Type [Value from 2019 to 2031]:

• Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors
• Botulinum Toxin
• Others

Tardive Dyskinesia Treatment Medicine Market by Application [Value from 2019 to 2031]:

• Hospital
• Clinic
• Others

Tardive Dyskinesia Treatment Medicine Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Tardive Dyskinesia Treatment Medicine Market

Tardive dyskinesia treatment medicine is a neurological condition characterized by involuntary, repetitive movements, often resulting from long-term use of antipsychotic medications. As the global incidence of TD rises due to the increased use of antipsychotics, there has been a notable shift towards developing more effective treatment options. Recent advances in treatment include the development of new medications and therapies that aim to reduce symptoms, improve patient quality of life, and minimize side effects. In countries like the United States, China, Germany, India, and Japan, the treatment landscape for tardive dyskinesia is evolving with new regulatory approvals, innovations, and increasing access to care.

• United States: In the United States, there has been a significant focus on new medications for tardive dyskinesia. Recently approved drugs, such as valbenazine and deutetrabenazine, are now more widely prescribed, offering patients more effective options for managing symptoms. These medications work by targeting neurotransmitters in the brain, specifically dopamine receptors, to reduce involuntary movements. Additionally, there has been a rise in awareness and diagnostic efforts supported by advocacy organizations and healthcare initiatives. Ongoing clinical trials for newer treatments, including gene therapies and neuromodulation devices, are shaping the future landscape of TD treatment in the U.S.
• China: China has seen a growing demand for tardive dyskinesia treatment due to the increasing use of antipsychotics, especially as mental health care access improves. While the treatment landscape remains somewhat limited compared to Western markets, there is a rising awareness of TD. Chinese healthcare providers are adopting newer medications that have been successful internationally, such as deutetrabenazine, though the availability of these drugs is still inconsistent across the country. Furthermore, local pharmaceutical companies are investing in the research and development of TD treatments, indicating future growth and more localized solutions in the coming years.
• Germany: Germany is witnessing considerable advancements in the treatment of tardive dyskinesia, with new drugs entering the market, such as valbenazine. The German healthcare system is well-equipped to handle specialized treatments, and regulatory approval processes for new therapies are relatively streamlined. The market is also benefiting from strong research collaborations and clinical trials that focus on improving therapeutic outcomes for patients with TD. Additionally, Germany is embracing digital health tools that can assist in monitoring patients and tailoring individualized treatment plans, helping doctors manage this complex condition more effectively.
• India: In India, tardive dyskinesia treatment is gaining more attention as the number of people receiving antipsychotic medications increases. However, access to new and advanced treatments for TD remains limited due to challenges with cost and availability. While traditional treatments like anticholinergics are still in use, newer medications, such as valbenazine, are slowly becoming available, though they are often out of reach for lower-income populations. Healthcare initiatives, along with increased awareness, are gradually improving diagnosis rates and encouraging early intervention. Growth in the Indian market is expected as healthcare infrastructure and access to modern medications improve.
• Japan: Japan is one of the leading countries in terms of advancements in medical technology and drug approval for tardive dyskinesia. The country has seen increased adoption of drugs like deutetrabenazine and valbenazine, both of which have proven effective in reducing symptoms of TD. Japan's regulatory process is relatively efficient, allowing for quick access to cutting-edge treatments. Furthermore, Japan is exploring the potential of innovative treatments such as gene therapy and neuromodulation, offering hope for more targeted and effective solutions for managing tardive dyskinesia in the future.

Features of the Global Tardive Dyskinesia Treatment Medicine Market

• Market Size Estimates: Tardive dyskinesia treatment medicine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Tardive dyskinesia treatment medicine market size by type, application, and region in terms of value ($B).
• Regional Analysis: Tardive dyskinesia treatment medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the tardive dyskinesia treatment medicine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tardive dyskinesia treatment medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the tardive dyskinesia treatment medicine market by type (vesicular monoamine transporter 2 (Vmat2) inhibitors, botulinum toxin, and others), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Tardive Dyskinesia Treatment Medicine Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors: Trends and Forecast (2019-2031)
• 4.4 Botulinum Toxin: Trends and Forecast (2019-2031)
• 4.5 Others: Trends and Forecast (2019-2031)

5. Global Tardive Dyskinesia Treatment Medicine Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital: Trends and Forecast (2019-2031)
• 5.4 Clinic: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Tardive Dyskinesia Treatment Medicine Market by Region

7. North American Tardive Dyskinesia Treatment Medicine Market

• 7.1 Overview
• 7.2 North American Tardive Dyskinesia Treatment Medicine Market by Type
• 7.3 North American Tardive Dyskinesia Treatment Medicine Market by Application
• 7.4 United States Tardive Dyskinesia Treatment Medicine Market
• 7.5 Mexican Tardive Dyskinesia Treatment Medicine Market
• 7.6 Canadian Tardive Dyskinesia Treatment Medicine Market

8. European Tardive Dyskinesia Treatment Medicine Market

• 8.1 Overview
• 8.2 European Tardive Dyskinesia Treatment Medicine Market by Type
• 8.3 European Tardive Dyskinesia Treatment Medicine Market by Application
• 8.4 German Tardive Dyskinesia Treatment Medicine Market
• 8.5 French Tardive Dyskinesia Treatment Medicine Market
• 8.6 Spanish Tardive Dyskinesia Treatment Medicine Market
• 8.7 Italian Tardive Dyskinesia Treatment Medicine Market
• 8.8 United Kingdom Tardive Dyskinesia Treatment Medicine Market

9. APAC Tardive Dyskinesia Treatment Medicine Market

• 9.1 Overview
• 9.2 APAC Tardive Dyskinesia Treatment Medicine Market by Type
• 9.3 APAC Tardive Dyskinesia Treatment Medicine Market by Application
• 9.4 Japanese Tardive Dyskinesia Treatment Medicine Market
• 9.5 Indian Tardive Dyskinesia Treatment Medicine Market
• 9.6 Chinese Tardive Dyskinesia Treatment Medicine Market
• 9.7 South Korean Tardive Dyskinesia Treatment Medicine Market
• 9.8 Indonesian Tardive Dyskinesia Treatment Medicine Market

10. ROW Tardive Dyskinesia Treatment Medicine Market

• 10.1 Overview
• 10.2 ROW Tardive Dyskinesia Treatment Medicine Market by Type
• 10.3 ROW Tardive Dyskinesia Treatment Medicine Market by Application
• 10.4 Middle Eastern Tardive Dyskinesia Treatment Medicine Market
• 10.5 South American Tardive Dyskinesia Treatment Medicine Market
• 10.6 African Tardive Dyskinesia Treatment Medicine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Tardive Dyskinesia Treatment Medicine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Teva Pharmaceutical
  • Company Overview
  • Tardive Dyskinesia Treatment Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Neurocrine Biosciences
  • Company Overview
  • Tardive Dyskinesia Treatment Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Sun Pharmaceutical
  • Company Overview
  • Tardive Dyskinesia Treatment Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 SteriMax
  • Company Overview
  • Tardive Dyskinesia Treatment Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Adamas Pharmaceuticals
  • Company Overview
  • Tardive Dyskinesia Treatment Medicine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us